Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis

Cancer Research

Volumn 61, Issue 13, 2001, Pages 5090-5101

  Viloria Petit, Alicia ^a   Kerbel, Robert S ^a   Jothy, Serge ^b   Crombet, Tania ^c   Hicklin, Daniel ^d   Bohlen, Peter ^d   Schlaeppi, Jean Marc ^e   Rak, Janusz ^f  

^a DUMC 3104   (United States)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^d ELI LILLY AND COMPANY   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CANCER THERAPY; DNA FINGERPRINTING; GENETIC TRANSFECTION; GROWTH RATE; HUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL GROWTH FACTORS; HUMANS; LYMPHOKINES; MICE; MICE, SCID; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035394833     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Inhibitors of tyrosine kinase
2. Therapeutic application of anti-growth factor receptor antibodies
3. Antibodies come back from the brink
4. The epidermal growth factor receptor and its inhibition in cancer therapy
5. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
6. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
7. Researchers describe findings for targeted cancer therapies
8. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
9. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
10. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody
11. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
12. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis
13. The epidermal growth factor receptor as a target for therapy in breast carcinoma
14. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
15. Cancer: Looking outside the genome
16. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors
17. Role of α1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571
18. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
19. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
20. Neutralizing antibodies against EGF and ErbB-2/neu receptor tyrosine kinases down-regulate VEGF production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
21. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells
22. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms
23. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor
24. Growth stimulation of A431 cells by epidermal growth factor: Identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody
25. A new monoclonal antibody for detection of EGF-receptors in western blots and paraffin-embedded tissue sections
26. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: Recovery of antagonistic activity
27. Characterization of a new potent, in vivo neutralizing monoclonal antibody to human vascular endothelial growth factor
28. Marked induction of the IAP family anti-apoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells
29. Multiple features of advanced melanoma recapitulated in tumorigenic variants of early stage (radial growth phase) human melanoma cell lines: Evidence for a dominant phenotype
30. Oncogenes and tumor angiogenesis: Differential modes of VEGF up-regulation in ras-transformed epithelial cells and fibroblasts
31. A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo
32. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy
33. The relationship between epidermal growth factor receptors and the terminal differentiation of A431 carcinoma cells
34. Reciprocal changes in p27(Kip1) and p21(Cipl) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors
35. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
36. ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner
37. ERbB-2 expression is rote-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation
38. Dominant-negative inhibition of FIk-1 suppresses the growth of many tumor types in vivo
39. Establishing a link between oncogenes and tumor angiogenesis
40. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/ vascular endothelial growth factor
41. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
42. Epidermal growth factor receptor in meningiomas is expressed predominantly on endothelial cells
43. Expression of growth factors and growth factor receptors in capillary hemangioblastoma
44. Blockade of EGF-R signaling inhibits resorption of bone and growth of human prostate cancer cells implanted into the tibias of nude mice
45. Phenotypic diversity of organ specific endothelial cells
46. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
47. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
48. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of C225 anti-epidermal growth factor receptor monoclonat antibodies
49. Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinomas
50. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis
51. Modulation of hypoxia-inducible factor la expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/ FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics
52. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia
53. pp60(cSrc) is a caspase-3 substrate and is essential for the transformed phenotype of A431 cells
54. Adaptor protein shc undergoes translocation and mediates upregulation of the tyrosine kinase c-Src in EGF-stimulated A431 cells
55. Impact of oncogenes on tumor angiogenesis: Mutant K-ras upregulation of VEGF/VPF is necessary but not sufficient for tumorigenicity of human colorectal carcinoma cells
56. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor
57. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
58. Induction of resistance to the Abelson inhibitor ST1571 in human leukemic cells through gene amplification